IN THIS ISSUE - Drug Development & Delivery

Recommendations

Info

Drug Development & Delivery July/August 2012 Vol 12 No 6 16 AmDerma & Oculus Enter Multi-Country Agreement AmDerma Pharmaceuticals, LLC, a privately owned company (and parent company of Quinnova Pharmaceuticals, Inc.) and Oculus Innovative Sciences recently announced the execution of an agreement to develop and commercialize Oculus’ novel proprietary Microcyn Technology drug compounds for major dermatological conditions, including acne. The exclusive agreement includes licensing of the dermatology compounds in the US and India, with a first right of refusal for all member states of the European Union, Canada, Brazil, and Japan. Oculus retains all rights for the rest of the world. Under the terms of the agreement, Oculus received an undisclosed upfront payment, and will receive multiple clinically based payments upon achievement of several development and regulatory milestones for both acne and secondary indications, as well as future escalating double-digit royalties on net sales of products. The agreement also memorializes the intent for future joint development of additional dermatological products and indications. "This agreement reflects the AmDerma/Quinnova commitment to the future of dermatology. Microcyn compounds have the potential to bring about significant advancement in the treatment of skin diseases, which affect millions of patients, without adding to the growing problem of antibiotic resistance or steroid overuse," said Jeffrey Day, Quinnova President. "Our dermatology customers have been pleased with improved patient outcomes as a result of adopting the Microcyn-based compounds for treatment of atopic dermatitis and related skin diseases. We look to build upon this success by growing the family of Microcyn-based dermatology compounds for myriad skin afflictions." AmDerma will be responsible for the development costs for the acne formulation as well as other dermatological compounds. "Oculus is thrilled to expand the scope of our existing partnership with Quinnova and its parent company, AmDerma. Quinnova is doing an exceptional job with the commercial launch of the Atrapro product, and we are confident they are the right partner to commercialize this technology in acne and other dermatological indications," said Hoji Alimi, Founder and President of Oculus.
Ambrx & Merck to Design & Develop Biologic Drug Conjugates Ambrx recently announced the company has entered into a collaboration with Merck to design and develop rationally optimized biologic drug conjugates based on Ambrx's site- specific protein medicinal chemistry technology. "Ambrx's technology has the potential to provide the foundation for a new family of biologic drug conjugates that selectively deliver small molecules to their site of action," said Peter G. Schultz, PhD, a scientific founder and board member. "Merck's deep disease area expertise made it the partner of choice in expanding the application of this technology beyond oncology to other important disease areas." Under the terms of the agreement, Merck gains worldwide rights to develop and commercialize biotherapeutic drug conjugates directed toward a number of pre-specified targets. Ambrx will receive an upfront payment of $15 million and is eligible to receive milestone payments totaling up to $288 million for successful discovery, development, and commercialization of candidates to all pre-specified targets. In addition, Ambrx will receive royalties on any net sales of products resulting from the collaboration. "Collaborations are an important part of our strategy to develop a portfolio of next-generation protein therapeutics that may offer significant benefits to patients," said Richard Murray, PhD, Senior Vice President and Head of Biologics and Vaccines Research at Merck. "This agreement will allow us to combine Ambrx's expertise in site-specific protein conjugation chemistry with Merck's expanding antibody capabilities and extensive small molecule resources." By combining the targeting properties of biologics with the potent therapeutic properties of small molecules, Merck and Ambrx plan to design and optimize new ways to specifically deliver pharmacologically active compounds to their site of action while minimizing the potential for systemic effects. Drug Development & Delivery July/August 2012 Vol 12 No 6 17
Page 1: July/August 2012 Vol 12 No 6 www.dr
Page 6: Drug Development & Delivery July/Au
Page 14 and 15: Drug Development & Delivery July/Au
Page 28 and 29: COMPOUND PROPERTIES: AN IMPORTANT P
Page 33 and 34: microneedle-mediated delivery as co
Page 35 and 36: Pharm Res. 2011;28(1):7-21. 7. Lee
Page 49 and 50: unit of up to 100 mg for iSPERSE. 2
Page 51 and 52: SPECIAL FEATURE Transdermal, Topica
Page 53 and 54: infusion pumps, the adhesive must r
Page 55 and 56: GMP manufacturing of supplies for P
Page 57: F I G U R E 8 Zosano’s ZP Patch T
Page 67:
Drug Development Deuterium Modifica
Page 70 and 71:
SPECIALTY PHARMA JULY/AUGUST 2012 V
Page 72 and 73:
SPECIALTY PHARMA JULY/AUGUST 2012 V
Page 74:
Drug Development & Delivery July/Au
show all

IN THIS ISSUE - Drug Development & Delivery

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?